3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Other
1
Myeloid
1
Lymphoid
1
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Myelodysplastic Syndromes
1
Mucositis
1
Lymphoma, Non-Hodgkin
1
Leukemia, Myeloid, Acute
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Hodgkin Disease
1
Interventions
Cyclophosphamide
72
Cytarabine
46
fludarabine phosphate
45
fludarabine
42
Vincristine
29
Filgrastim
27
Peripheral Blood Stem Cell Transplantation
25
Methotrexate
25
Etoposide
24
Dexamethasone
23
Melphalan
21
Rituximab
20
Doxorubicin
19
Clofarabine
19
Tacrolimus
17
Mycophenolic Acid
17
Dasatinib
16
Bortezomib
15
Whole-Body Irradiation
14
Vorinostat
14
pegaspargase
13
Cyclosporine
13
Calcium Dobesilate
13
Busulfan
13
Antilymphocyte Serum
12
tanespimycin
10
Topotecan
10
Stem Cell Transplantation
10
Specimen Handling
10
Sirolimus
10
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Precursor Cell Lymphoblastic Leukemia-Lymphoma
×
angiotensin I (1-7)
×
Clear all
NCT01300611
2020-12-08
USBTXA127CBT
Tarix Pharmaceuticals
Phase 1
Terminated
20 enrolled